Tie J, Cohen JD, Wang Y, et al. - Researchers examined the value of serial postsurgical and postchemotherapy circulating tumor DNA (ctDNA) analysis in determining the efficacy of adjuvant chemotherapy in patients with stage III colon cancer. In this multicenter, Australian, population-based cohort biomarker study, 96 patients with stage III colon cancer were analyzed. Outcomes revealed a significant difference in the 3-year recurrence-free interval in patients with detectable vs undetectable levels of circulating tumor DNA after surgery (47% vs 76%) and after completion of chemotherapy (30% vs 77%). Findings thereby suggest that patients at high risk of recurrence, despite completing standard adjuvant treatment, could be identified via performing postsurgical and postchemotherapy circulating tumor DNA analyses. This presents a unique opportunity to explore additional therapeutic approaches.